BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 17, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 10, 2003
View Archived Issues
Monoclonal antibodies that inhibit collagen-bacteria binding and their therapeutic use
Read More
Novel PPAR agonists developed by GSK scientists
Read More
Roche team prepares novel p38 kinase inhibitors
Read More
Novartis presents new IOP-lowering agents in recent patent
Read More
Several series of glycogen phosphorylase inhibitors described by AstraZeneca
Read More
New PDE4 inhibitors for inflammation, allergy, etc., under study at Ono
Read More
Phase III trial initiated for Bio-E-Gel
Read More
Genzyme and Transkaryotic enter agreement for I2S for Hunter's syndrome
Read More
IDN-6556 evaluated in liver transplant patients in new phase II trial
Read More
ILX-651 enters new phase II study in melanoma
Read More
FDA accepts Vitrase NDA for filing
Read More
Phase II/III study evaluates NGX-4010 for HIV/AIDS-associated neuropathic pain
Read More
Novartis and Sankyo to codevelop and commercialize new GERD treatment
Read More
Approvable letter for insulin detemir
Read More
Dosing completed in TOP study of Preos
Read More
Proof-of-concept study of teduglutide for Crohn's disease
Read More
Vernalis formed from merger of Vernalis, British Biotech and RiboTargets
Read More
Nymox develops neurodegenerative disease drug candidate
Read More
PI-0824 evaluated in new phase I trial in patients with pemphigus vulgaris
Read More
Successful completion of phase I trial of Tbeta4
Read More
Teva seeks marketing approval for rasagiline in Canada
Read More
Dalbavancin compared to vancomycin in new phase III trial
Read More
TA-NIC enters second phase I trial
Read More
Garenoxacin as a promising option for community-acquired respiratory tract infections
Read More
Acceptable toxicity profile described for GEM-231 against refractory solid tumors
Read More
Increased tissue levels of resiniferatoxin in pig bladder wall after electrical stimulation
Read More
High discontinuation rate found with long-term anticholinergic therapy for OAB
Read More